4th Palermo Conference on INNOVATIVE THERAPIES FOR LYMPHOID MALIGNANCIES
Published online 1 February 2009
Haematologica, Vol 94, Issue 2, 280-284 doi:10.3324/haematol.13052
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lewintre, E. J.
Right arrow Articles by García-Conde, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lewintre, E. J.
Right arrow Articles by García-Conde, J.

Chronic Lymphocytic Leukemia

Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia

Eloisa Jantus Lewintre1, Cristina Reinoso Martín1, Carlos García Ballesteros2, David Montaner3, Rosa Farrás Rivera1, José Ramón Mayans2, Javier García-Conde1,4

1 Molecular Haematology Laboratory, Prince Felipe Research Centre, Valencia
2 Haematology Department, Arnau de Vilanova Hospital, Valencia
3 Bioinformatic Department, Prince Felipe Research Centre, Valencia and
4 University of Valencia, Valencia, Spain

Correspondence: Eloisa Jantus Lewintre, PhD., Molecular Haematology Laboratory, Prince Felipe Research Centre, Avda Autopista El Saler 16-3, 46012, Valencia, Spain. E-mail:ejantus{at}cipf.es

Chronic lymphocytic leukemia is an adult-onset leukemia with a heterogeneous clinical behavior. When chronic lymphocytic leukemia cases were divided on the basis of IgVH mutational status, widely differing clinical courses were revealed. Since IgVH sequencing is difficult to perform in a routine diagnostic laboratory, finding a surrogate for IgVH mutational status seems an important priority. In the present study, we proposed the use of Cryptochrome-1 as a new prognostic marker in early-stage chronic lymphocytic leukemia. Seventy patients (Binet stage A, without treatment) were included in the study. We correlated Cryptochrome-1 mRNA with well established prognostic markers such as IgVH mutations, ZAP70, LPL or CD38 expression and chromosomal abnormalities. High Cryptochrome-1 expression correlated with IgVH unmutated samples. In addition, Cryptochrome-1 was a valuable predictor of disease progression in early-stage chronic lymphocytic leukemia, therefore it can be introduced in clinical practice with the advantage of a simplified method of quantification.

Key words: Cryptochrome-1, prognostic marker, chronic lymphocytic leukemia, ZAP70, LPL, IgVH.